Intra Cellular Therapies reported $-72119000 in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Acadia Pharmaceuticals ACAD:US $ -113.06M 69.96M
ALKERMES ALKS:US $ -35.9M 36.78M
Aptinyx Inc APTX:US $ -19827000 217K
Biocryst Pharmaceuticals BCRX:US $ -74.2M 56.42M
Biogen BIIB:US $ 303.8M 64.4M
Bristol Myers Squibb BMY:US $ 1278M 1094M
Cytokinetics CYTK:US $ -89.44M 58.88M
Esperion Therapeutics ESPR:US $ -56731000 8.39M
Gilead Sciences GILD:US $ 19M 363M
Halozyme Therapeutics HALO:US $ 60.11M 6.66M
Intra Cellular Therapies ITCI:US $ -72.12M 13.62M
Johnson & Johnson JNJ:US $ 5149M 413M
Marinus Pharmaceuticals MRNS:US $ -19.36M 8.94M
Minerva Neurosciences NERV:US $ -9.76M 11.54M
Nektar Therapeutics NKTR:US $ -90.39M 55.25M
Neurocrine Biosciences NBIX:US $ 13.9M 21.2M
Novartis NVS:US $ 2222M 14086M
Prothena PRTA:US $ -36.29M 3.11M
Supernus Pharmaceuticals SUPN:US $ 25.62M 23.17M
United Therapeutics UTHR:US $ 239.9M 127.7M
Vanda Pharmaceuticals VNDA:US $ -6.43M 13.51M